Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma

被引:89
作者
Mårtenson, ED
Hansson, LO
Nilsson, B
von Schoultz, E
Brahme, EM
Ringborg, U
Hansson, J
机构
[1] Karolinska Hosp, Radiumhemmet, Dept Oncol, S-17176 Stockholm, Sweden
[2] Karolinska Hosp, Radiumhemmet, Dept Clin Chem, S-17176 Stockholm, Sweden
[3] Karolinska Hosp, Radiumhemmet, Dept Canc Epidemiol, S-17176 Stockholm, Sweden
关键词
D O I
10.1200/JCO.2001.19.3.824
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate whether S-100B protein in serum is an independent prognostic marker in malignant melanoma. Materials and Methods: S-100B protein in serum was analyzed in 1,007 consecutive patients with histologically verified cutaneous malignant melanoma, At the time of blood sampling, 876 patients were in clinical stage I, 35 were in stage II, and 96 were in stage III. The serum concentrations of 5-1008 protein were measured by a luminescence immunoassay (LIA), Results: The mean serum concentration of S-100B protein was significantly related to clinical stage, with the lowest level in stage I and the highest in stage III. In a multivariate analysis, S-100B protein levels in serum showed the strongest prognostic impact of the factors analysed with respect to disease-specific survival in clinical stages II to III, followed by clinical stage. Serum S-100B protein was not a significant independent prognostic factor in clinical stage I, where tumor thickness showed the strongest relation to melanoma specific survival, followed by ulceration and satellites, Conclusion: This investigation contains the largest material of patients so far analyzed with the new LIA assay of S-100B protein in serum and confirms that S-100B protein in serum is correlated with clinical stage and is an independent prognostic marker in clinical stages II and III. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:824 / 831
页数:8
相关论文
共 37 条
[1]   Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma [J].
Abraha, HD ;
Fuller, LC ;
DuVivier, AWP ;
Higgins, EM ;
Sherwood, RA .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 137 (03) :381-385
[2]  
ARMITAGE P, 1985, STAT METHODS MED RES, P189
[3]   MULTIFACTORIAL ANALYSIS OF MELANOMA - PROGNOSTIC HISTOPATHOLOGICAL FEATURES COMPARING CLARKS AND BRESLOWS STAGING METHODS [J].
BALCH, CM ;
MURAD, TM ;
SOONG, SJ ;
INGALLS, AL ;
HALPERN, NB ;
MADDOX, WA .
ANNALS OF SURGERY, 1978, 188 (06) :732-742
[4]   CHARACTERIZATION OF THE TUMOR SUPPRESSOR PROTEIN-P53 AS A PROTEIN-KINASE-C SUBSTRATE AND A S100B-BINDING PROTEIN [J].
BAUDIER, J ;
DELPHIN, C ;
GRUNWALD, D ;
KHOCHBIN, S ;
LAWRENCE, JJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) :11627-11631
[5]   The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma [J].
Bonfrer, JMG ;
Korse, CM ;
Nieweg, OE ;
Rankin, EM .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2210-2214
[7]   HEMATOGENOUS SPREAD OF MALIGNANT-MELANOMA CELLS IN DIFFERENT STAGES OF DISEASE [J].
BROSSART, P ;
KEILHOLZ, U ;
WILLHAUCK, M ;
SCHEIBENBOGEN, C ;
MOHLER, T ;
HUNSTEIN, W .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 101 (06) :887-889
[8]   Elevated serum levels of S100 and survival in metastatic malignant melanoma [J].
Buer, J ;
Probst, M ;
Franzke, A ;
Duensing, S ;
Haindl, J ;
Volkenandt, M ;
Wittke, F ;
Hoffmann, R ;
Ganser, A ;
Atzpodien, J .
BRITISH JOURNAL OF CANCER, 1997, 75 (09) :1373-1376
[9]   PROGNOSTIC VALUE OF SIZE OF LYMPH-NODE METASTASES IN PATIENTS WITH CUTANEOUS MELANOMA [J].
BUZAID, AC ;
TINOCO, LA ;
JENDIROBA, D ;
TU, ZN ;
LEE, JJ ;
LEGHA, SS ;
ROSS, MI ;
BALCH, CM ;
BENJAMIN, RS .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2361-2368
[10]  
BUZAID AC, 1998, CUTANEOUS MELANOMA, P34